BIOGEN INC. (BIIB) earnings date, results and what the price requires
Nasdaq · SEC CIK 0000875045 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 29, 2026 | Announced; figures arrive with the 10-Q | — | — | Filing |
| Mar 31, 2026 | Apr 29, 2026 | $2.48B | $319.5M | $2.15 | Filing |
| Dec 31, 2025 | Jan 14, 2026 | $2.28B | $-48.8M | $-0.35 | Filing |
| Sep 30, 2025 | Oct 14, 2025 | $2.53B | $466.5M | $3.17 | Filing |
| Jun 30, 2025 | Jul 31, 2025 | $2.65B | $634.8M | $4.33 | Filing |
| Mar 31, 2025 | May 1, 2025 | $2.43B | $240.5M | $1.64 | Filing |
| Dec 31, 2024 | Feb 12, 2025 | $2.45B | $266.5M | $1.82 | Filing |
| Sep 30, 2024 | Oct 30, 2024 | $2.47B | $388.5M | $2.66 | Filing |
| Jun 30, 2024 | Aug 1, 2024 | $2.46B | $583.6M | $4.00 | Filing |
What would BIOGEN INC. have to report for its valuation to change?
At $232.65, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 16.4% a year, to $19.89. On that path the next quarter needs diluted EPS near $5.04, against $4.33 in the quarter ended Jun 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 16.4% | 16.4% |
| EPS needed in final year | $19.89 | $19.89 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. BIIB goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.